Advanced Nanobiomed Research最新文献_第5页

Advances and Challenges in Micro/Nanocarrier-Based Dermal Drug Delivery Systems for Acne Treatment 基于微/纳米载体的皮肤给药系统治疗痤疮的进展和挑战

IF 4.4

Advanced Nanobiomed Research Pub Date : 2026-04-04 Epub Date: 2026-01-16 DOI: 10.1002/anbr.202500184

Jintao Yang, Jie Chen, Yunmiao Ma, Qingwei Zhou, Yu Kong, Yingxiang Chen, Junjie Chi, Haihua Hu

{"title":"Advances and Challenges in Micro/Nanocarrier-Based Dermal Drug Delivery Systems for Acne Treatment","authors":"Jintao Yang, Jie Chen, Yunmiao Ma, Qingwei Zhou, Yu Kong, Yingxiang Chen, Junjie Chi, Haihua Hu","doi":"10.1002/anbr.202500184","DOIUrl":"10.1002/anbr.202500184","url":null,"abstract":"Acne vulgaris is a prevalent chronic inflammatory skin disease, for which topical pharmacotherapy remains challenging due to the skin barrier and complex pathological mechanisms. In recent years, micro/nanocarrier-based dermal delivery systems have emerged as novel strategies to overcome these barriers. These carriers can significantly enhance local drug bioavailability, targeting precision, and therapeutic duration. Furthermore, by integrating functionally complementary carriers, synergistic effects can be achieved across spatial, temporal, and biological dimensions, offering a systematic intervention for this multifactorial condition. However, the clinical translation of such technologies is still hindered by several challenges, including scalable manufacturing processes, long-term safety evaluation, reliable preclinical models, and harmonized regulatory standards. Looking forward, the convergence of multiomics diagnostics and digital manufacturing is expected to advance intelligent closed-loop systems capable of real-time sensing and adaptive regulation, thereby enabling truly personalized and precise treatment. This progress will shift acne management from symptomatic control toward modulation of the underlying pathology.","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"6 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500184","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147683734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fast-Track to Functional Neurons: Accessible and Minimalistic Neurogenin 2 Programming of Human iPSCs 功能性神经元的快速通道：人类iPSCs的易于获取和简约的神经原素2编程

IF 4.4

Advanced Nanobiomed Research Pub Date : 2026-04-04 Epub Date: 2026-02-18 DOI: 10.1002/anbr.202500221

Jann Harberts, Malte Siegmund, Emma Wollesen, Caroline Viola, Kim Krieg, Ole Pless, Roey Elnathan, Robert Zierold, Robert H. Blick, Nicolas H. Voelcker

{"title":"Fast-Track to Functional Neurons: Accessible and Minimalistic Neurogenin 2 Programming of Human iPSCs","authors":"Jann Harberts, Malte Siegmund, Emma Wollesen, Caroline Viola, Kim Krieg, Ole Pless, Roey Elnathan, Robert Zierold, Robert H. Blick, Nicolas H. Voelcker","doi":"10.1002/anbr.202500221","DOIUrl":"10.1002/anbr.202500221","url":null,"abstract":"Neuronal differentiation of human induced pluripotent stem cells (hiPSCs) is a cornerstone for advancing neuroscience research and therapeutic applications. However, conventional differentiation protocols are commonly resource-intensive, technically complex, and overall time-consuming—often requiring several weeks to months to yield functional neurons. Here, a streamlined method is presented to enable fast and reliable neurogenin 2 (NGN2)-mediated neuronal differentiation by introducing the “colony-initiated differentiation” (CID) approach. The CID method yields functional neurons from a commercially available hiPSC line (BIONi010-C-13, equipped with a doxycycline (DOX)-inducible NGN2 expression cassette) in just five days. Within the first two days of CID, the colonies undergo a structural reorganization, after which the cells are replated and mature for additional 3–5 days. The neurons become functional from day five onward, demonstrated by patch clamp recordings of action potentials. Critically, CID operates entirely feeder cell- and growth factor-free. Simplicity, regular-workday compatibility, and quality of the differentiation method using a market-available hiPSC line make the method easily accessible to researchers across various fields. Thus, this work not only has implications for accelerating research in toxicity screening and drug discovery but particularly in multidisciplinary fields such as materials science and bioengineering, providing a robust platform to study neuron–material interfaces and interactions.","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"6 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500221","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147683777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanostructured Lipid Carriers Overcome the Low Immunogenicity of M2e Peptide via Surface Click Chemistry Conjugation, Improving the Anti-M2e Antibody Response 纳米结构脂质载体通过表面点击化学偶联克服M2e肽的低免疫原性，提高抗M2e抗体应答

IF 4.4

Advanced Nanobiomed Research Pub Date : 2026-04-04 Epub Date: 2026-02-15 DOI: 10.1002/anbr.202500236

Louis Bourlon, Carole Fournier, Antoine Hoang, Christine Charrat, Alban Lepetitcolin, Jessica Morlieras, Fabrice Navarro, Patrice N. Marche

{"title":"Nanostructured Lipid Carriers Overcome the Low Immunogenicity of M2e Peptide via Surface Click Chemistry Conjugation, Improving the Anti-M2e Antibody Response","authors":"Louis Bourlon, Carole Fournier, Antoine Hoang, Christine Charrat, Alban Lepetitcolin, Jessica Morlieras, Fabrice Navarro, Patrice N. Marche","doi":"10.1002/anbr.202500236","DOIUrl":"https://doi.org/10.1002/anbr.202500236","url":null,"abstract":"Influenza vaccines targeting hemagglutinin require annual updates due to viral variability, limiting protection against pandemic strains. The conserved matrix protein 2 ectodomain (M2e) peptide offers cross-strain immunity but suffers from low immunogenicity. Here, M2e peptides are conjugated onto nanostructured lipid carriers (NLCs) using bioorthogonal click chemistry, preserving key epitopes and enhancing antigen presentation. Immunization in mice demonstrates that NLC-M2e induces focused and robust anti-M2e antibody responses, which are significantly amplified by incorporating a pan-DR epitope helper T cell epitope, achieving antibody levels compatible with protection. The formulation elicits balanced IgG subclasses and T-helper 1 cell-type cellular responses, supporting effective immune mechanisms. These findings suggest that NLC-based delivery of M2e peptides, especially with helper epitopes, represents a promising universal influenza vaccine strategy warranting further preclinical and clinical investigation.","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"6 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500236","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147686208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mucin Glycoprotein Nanoparticles Enable a Selective Antisense Therapy for Oncogenic MicroRNAs 粘蛋白糖蛋白纳米颗粒可选择性反义治疗致癌microrna

IF 4.4

Advanced Nanobiomed Research Pub Date : 2026-04-04 Epub Date: 2026-01-04 DOI: 10.1002/anbr.202500210

Ceren Kimna, Thomas Mayer, Di Zhang, Matthias Marczynski, Carolin A. Rickert, Fabio Henkel, Lennart J. K. Weiss, Friedrich C. Simmel, Yuxia Luan, Oliver Lieleg

{"title":"Mucin Glycoprotein Nanoparticles Enable a Selective Antisense Therapy for Oncogenic MicroRNAs","authors":"Ceren Kimna, Thomas Mayer, Di Zhang, Matthias Marczynski, Carolin A. Rickert, Fabio Henkel, Lennart J. K. Weiss, Friedrich C. Simmel, Yuxia Luan, Oliver Lieleg","doi":"10.1002/anbr.202500210","DOIUrl":"https://doi.org/10.1002/anbr.202500210","url":null,"abstract":"MicroRNAs (miRNAs) are critical regulators of gene expression, and their dysregulated expression has been implicated in the context of various diseases. Despite their therapeutic potential, the physicochemical instability and off-target effects of miRNA-targeting therapeutics pose significant challenges. To address this, the first antisense formulation is here developed based on highly biocompatible mucin glycoproteins, where the molecular cargo, synthetic DNA strands, has a dual functionality: stabilizing the structure of mucin glycoproteins into nanoparticles and enabling sequence-specific binding to oncogenic miRNA. These condensed nanoparticles leverage the intrinsic properties of mucins and can be modified with targeting ligands to enhance the specificity of cellular uptake. Findings demonstrate that mucin nanoparticles demonstrate therapeutic potential by inhibiting tumor growth in vivo. This presented approach not only enhances the specificity of nucleic acid delivery but also opens the door for the development of personalized diagnostics and therapies for diseases characterized by cell-specific overexpression of RNAs.","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"6 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500210","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147686920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polyphenol-Based Biomaterials Against Cancer Radio/Chemotherapy-Induced Intestinal Toxicity 多酚类生物材料抗肿瘤放化疗肠道毒性研究

IF 4.4

Advanced Nanobiomed Research Pub Date : 2026-04-04 Epub Date: 2026-02-18 DOI: 10.1002/anbr.202500239

Jixu Lu, Jing Chen, Ji Zhu, Lixin Ru, Dongxiao Zhang

引用次数: 0

Engineering Tertiary Lymphoid Structures: Nanomedicine, Bioengineering, and Biomaterials for Precision Immunotherapy 工程三级淋巴结构：纳米医学、生物工程和精密免疫治疗的生物材料

IF 4.4

Advanced Nanobiomed Research Pub Date : 2026-04-04 Epub Date: 2026-01-16 DOI: 10.1002/anbr.202500220

Shaza Karaman, Mei ElGindi, Jeremy Teo

{"title":"Engineering Tertiary Lymphoid Structures: Nanomedicine, Bioengineering, and Biomaterials for Precision Immunotherapy","authors":"Shaza Karaman, Mei ElGindi, Jeremy Teo","doi":"10.1002/anbr.202500220","DOIUrl":"10.1002/anbr.202500220","url":null,"abstract":"Tertiary lymphoid structures (TLSs) are inducible, ectopic aggregates that mirror the architecture and immunological functions of secondary lymphoid organs, arising in nonlymphoid tissues during chronic inflammation, infection, autoimmunity, and cancer. Their ability to orchestrate local antigen presentation, lymphocyte activation, and germinal center reactions supports their critical roles in both protective immunity and disease pathogenesis. Recent breakthroughs in biomaterials science and nanotechnology have enabled the rational design and manipulation of the stromal and molecular microenvironmental cues necessary for TLS neogenesis, maturation, and modulation. This review collates recent advances in TLS biology with the latest developments in engineering strategies, including the use of hydrogels as scaffolding matrices, nanoparticles, and other microstructured materials, aimed at inducing, supporting, or modulating TLS both in vivo and in vitro. This review critically assess how material properties, cytokine delivery, and cellular engineering can recapitulate or enhance key stromal–immune interactions that drive TLS formation. Furthermore, the translational implications of biomaterial- and nanoparticle-based TLS engineering are examined, highlighting preclinical applications in cancer immunotherapy, autoimmune disorders, and tissue regeneration. Finally, major challenges and future perspectives toward utilizing engineered TLS as customizable, site-specific immunotherapeutic platforms for precision medicine are discussed.","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"6 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500220","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147683733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 4.4

Advanced Nanobiomed Research Pub Date : 2026-03-25